Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxBreakthrough Brings Potential Glioblastoma Drug Into Focus

Researchers have identified a small molecule, named as SHP656, that can target the brain’s clock proteins and may prove effective for treating glioblastoma.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form